WuXi PharmaTech (Cayman) Inc.
288 FuTe ZhongLu
Waigaoqiao Free Trade Zone
Shanghai,
200131
China - Map
Phone: 86 21 5046 1111
Fax: 86 21 5046 1000
Web Site: http://www.wuxipharmatech.com
| WuXi PharmaTech (Cayman) Inc., through its subsidiaries, operates as a pharmaceutical, biotechnology, and medical device research and development outsourcing company in the Peoples Republic of China and the United States. The company provides laboratory services for pharmaceutical companies, which include discovery and medicinal chemistry, analytical chemistry, discovery biology, safety pharmacology, bioanalytical services, process research, formulation, and toxicology services, as well as drug metabolism and pharmacokinetics/absorption, distribution, metabolism, and excretion services. It also offers services in antibody generation, cell line development, and biologics safety testing that support customers biologics product development and commercialization; and medical device testing and development services. In addition, the company provides manufacturing services for producing advanced intermediates and active pharmaceutical ingredients for use by pharmaceutical companies in preclinical and clinical trials. It offers its services directly to pharmaceutical, biotechnology, and medical device companies. The company was founded in 2000 and is headquartered in Shanghai, the Peoples Republic of China. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Ge Li Ph.D., 42
Co-Founder, Chairman, Chief Exec. Officer, Member of Strategy Committee and Member of Compensation Committee |
N/A
| N/A | Mr. Xiaozhong Liu , 44
Co-Founder, Exec. VP |
N/A
| N/A | Dr. Ning Zhao Ph.D.,
Co-Founder, Lead Advisor of Analytical Services Operations |
N/A
| N/A | Mr. Zhaohui Zhang , 39
Co-Founder, VP of Domestic Marketing |
N/A
| N/A | Mr. Edward Hu M.B.A, 46
Chief Operating Officer and Interim Chief Financial Officer |
N/A
| N/A |
|
|
|
Dollar amounts are as of
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 
Profile
